

# JOIN GENERATION LIBERATION

**Nityr**<sup>®</sup>  
nitisinone  
Tablets

PATIENTS WITH TYROSINEMIA TYPE 1, KNOW YOUR OPTIONS  
AND START THE CONVERSATION WITH YOUR DOCTOR TODAY!

*NITYR<sup>®</sup> (nitisinone) Tablets are a hydroxyphenyl-pyruvate dioxygenase inhibitor indicated for the treatment of adult and pediatric patients with **Hereditary Tyrosinemia Type 1 (HT-1)** in combination with dietary restriction of tyrosine and phenylalanine.*

## Introducing NITYR

NITYR is designed with convenience in mind, putting your needs first, both now and in the future. NITYR Tablets are:

- Room temperature stable
- Easy to give, easy to take
- Able to be taken with or without food, requiring no mealtime restrictions
- Bioequivalent to Orfadin\* (nitisinone) capsules<sup>1</sup>
- Available with financial assistance including the 30-Day Free NITYR Program\*\* and a \$0 copay for eligible patients<sup>§</sup>



### Try. Compare. Decide.

You have the opportunity to *try* the NITYR Experience, *compare* it to your current nitisinone medication and *decide* if NITYR is right for you and your family – all without any interference at any level to your current NTBC supply.

Eligibility criteria apply.\*\*

Start the NITYR Experience today with the 30-Day Free NITYR Program.\*\*

Find out more at [www.nityr.us](http://www.nityr.us)

As part of the NITYR Experience, our Patient Liaison Support and Clinical Metabolic Support Teams are available 24/7, to support you every step of the way.

**If you think NITYR is right for you and your family, start the conversation with your doctor today. Use this guide as a framework to help you feel confident in getting the answers you need when speaking to your doctor about NITYR.**

References: 1. Data on file: REF-00001. \*Orfadin is a registered trademark, licensed by Swedish Orphan Biovitrum AB (publ) and is marketed by Sobi, Inc. \*\*30-Day Free NITYR Program: Patients can try NITYR for 30 days, one time, for free, as long as their doctor prescribes it. Subject to terms and conditions, eligibility criteria, and other federal and state law. Terms and Conditions and eligibility criteria are available at [www.nityr.us/offerstcs](http://www.nityr.us/offerstcs). §\$0 co-pay for eligible commercially insured patients within specified limits and relevant terms and conditions.

# Questions to consider asking your doctor

## Treatment

- Is NITYR any different to the NTBC (nitisinone) I am already taking? Are the side effects and safety any different to my current NTBC?
- Would my diet change if I am prescribed NITYR rather than my current NTBC?
- What is NITYR and how does it work?
- How is NITYR taken/given? Would it be different to how I take/give nitisinone at the moment?
- Will my diet plan change if I take NITYR?
- How should NITYR be stored or transported?
- Can NITYR be taken without food?
- Can I take my dose of NITYR once a day?
- How might NITYR support me in living with Tyrosinemia Type 1?
- How can I try NITYR?

## Product Support

- What product support comes with NITYR? Is it any different to the product support I already have with my current NTBC?
- Is there dietary product support available with NITYR?
- Will there be someone I can contact when I have questions? (i.e., with navigating insurance requirements or staying on top of medication refills.)

## Next steps

- I'm still unsure, is there a way to try NITYR without committing?
- How can I find out if NITYR is covered by my insurance provider? Will I have to pay more for NITYR?
- I'm interested in the 30-Day Free NITYR Program, what do I do next?\*

For more information on NITYR please visit [www.nityr.us](http://www.nityr.us)

### With you every step of the way

Connect with Patient Liaison Support anytime you have a question or concern. Call 1-800-775-5783.

Please see Important Safety Information below and full Prescribing Information at [www.nityr.us/pi](http://www.nityr.us/pi)

# Important Safety Information

## Indication and Usage

NITYR<sup>®</sup> (nitisinone) Tablets are a competitive inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.

## Important Safety Information

Do not take NITYR if you are allergic to nitisinone or any other ingredients. Tell your healthcare professional about any health problems, and if you are pregnant or planning to become pregnant and/or breastfeeding, before starting treatment.

## Warnings and Precautions

### Increased levels of plasma tyrosine, eye symptoms, developmental delay and skin changes:

- Inadequate restriction of tyrosine and phenylalanine intake can result in elevations of plasma tyrosine.
- Plasma tyrosine levels above 500 micromol/L may lead to ocular signs and symptoms including corneal ulcers, corneal opacities, keratitis, conjunctivitis, eye pain, and photophobia, intellectual disability and developmental delay or painful hyperkeratotic plaques (thickening of the skin) on the soles and palms.
- Your healthcare provider should not adjust NITYR dosage in order to lower the levels of tyrosine in the blood.
- Your healthcare provider will obtain a slit-lamp examination prior to initiating NITYR treatment, regularly during treatment and may reexamine you if you develop symptoms or if your tyrosine levels are above 500 micromol/L.

### Changes in blood profile

- You may develop leukopenia (reduction in the number of white blood cells, which form part of the immune system) and severe thrombocytopenia (abnormally low levels of platelets, which help the blood to clot).
- Your healthcare provider will monitor platelet and white blood cell counts, and will adjust your medication accordingly.

## Adverse reactions

The most common adverse reactions ( $\geq 1\%$ ) in patients with HT-1 taking nitisinone are elevated tyrosine levels, low platelets (thrombocytopenia) or white cells in the blood (leukopenia), and complaints related to the eyes, including conjunctivitis, corneal opacity, inflammation of the cornea, eye pain and extreme sensitivity to light (photophobia), nosebleed (epistaxis), itching (pruritus), skin inflammation (exfoliative dermatitis), rash (maculopapular rash), dry skin and alopecia.

If you have a question about your dosage, or if you experience any of the symptoms explained above, please speak to your healthcare provider.

Keep NITYR and all medicines out of reach of children.

For more detailed information, please refer to the full prescribing information at [www.nityr.us/pi](http://www.nityr.us/pi).

**If you get any side effects, talk to your healthcare provider. This includes possible side effects not listed in this guide. You may also report side effects directly by calling Cycle Pharmaceuticals at 1-855-831-5413 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**